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Calcium/calmodulin-dependent kinase kinase 2
regulates hematopoietic stem and progenitor cell
regeneration
Luigi Racioppi*,1,2,4, William Lento1,4, Wei Huang1, Stephanie Arvai1, Phuong L Doan1, Jeffrey R Harris1, Fernando Marcon3,
Helder I Nakaya3, Yaping Liu1 and Nelson Chao1
Hematopoietic stem and progenitor cells (HSPCs) are predominantly quiescent in adults, but proliferate in response to bone
marrow (BM) injury. Here, we show that deletion of Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) promotes
HSPC regeneration and hematopoietic recovery following radiation injury. Using Camkk2-enhanced green fluorescent protein
(EGFP) reporter mice, we found that Camkk2 expression is developmentally regulated in HSPC. Deletion of Camkk2 in HSPC
results in a significant downregulation of genes affiliated with the quiescent signature. Accordingly, HSPC from Camkk2 null mice
have a high proliferative capability when stimulated in vitro in the presence of BM-derived endothelial cells. In addition, Camkk2
null mice are more resistant to radiation injury and show accelerated hematopoietic recovery, enhanced HSPC regeneration and
ultimately a prolonged survival following sublethal or lethal total body irradiation. Mechanistically, we propose that CaMKK2
regulates the HSPC response to hematopoietic damage by coupling radiation signaling to activation of the anti-proliferative AMP-
activated protein kinase. Finally, we demonstrated that systemic administration of the small molecule CaMKK2 inhibitor, STO-609,
to irradiated mice enhanced HSPC recovery and improved survival. These findings identify CaMKK2 as an important regulator of
HSPC regeneration and demonstrate CaMKK2 inhibition is a novel approach to promoting hematopoietic recovery after BM injury.
Cell Death and Disease (2017) 8, e3076; doi:10.1038/cddis.2017.474; published online 5 October 2017
Hematopoietic stem and progenitor cells (HSPCs) reside in
specialized bone marrow (BM) niches that provide signals to
ensure blood production and maintain the long-term hemato-
poietic stem cell (LT-HSC) pool. Extensive studies of the niche
have identified several cell types such as osteoblasts,1
endothelial cells,2 osteomacs,3 regulatory T cells4 and
sympathetic neurons5 as contributors of the physiologic
microenvironment.6,7 These cells engage HSPC through both
physical contacts and soluble paracrine signaling molecules
including CXC chemokine ligand 12 (CXCL12), stem cell
factor (SCF), non-canonical and canonical Wnt ligands, and
epidermal growth factor8,9 to control niche retention and self-
renewal. Although these molecules may trigger calcium
transients, the role of calcium-dependent cascades in the
mechanism regulating HSCP regeneration has not been
elucidated.10–13
Calmodulin (CaM) is the primary intercellular calcium
sensor and binding to free cytosolic Ca2+ causes conforma-
tional changes that facilitate its interaction with the multi-
functional Ser/Thr kinases Ca2+/CaM-dependent protein
kinase I, IV (CaMKI and CaMKIV, respectively) and Ca2
+/CaM-dependent protein kinase kinase 1 (CaMKK1) and
CaMKK2 to activate Ca2+/CaM-dependent signaling
cascades.14,15 CaMKK2 activation permits phosphorylation
of CaMKI, CaMKIV and the adenosine monophosphate
activated protein kinase (AMPK).16 The expression of
CaMKK2 is relatively cell type restricted and outside the brain
it is found in osteoblasts,17 macrophages18 and myeloid
progenitors.19
Here, we demonstrate CaMKK2 functions as a critical kinase
that regulates the regeneration of HSPC. CaMKK2 deficiency
downregulates genes affiliated with stem cell quiescence and
causes a HSPC hyper-proliferative phenotype in vitro and
accelerates hematopoietic recovery following radiation injury
in vivo. Mechanistically, we demonstrate CaMKK2 is required to
link radiation injury with AMPK activation and p53 accumulation.
Importantly, the transient inhibition of CaMKK2 with the small
molecule CaMKK2 kinase inhibitor STO-60920 improves survi-
val and hematopoietic regeneration.
Results
CaMKK2 expression is enriched in HSPC in vivo. We
used CaMKK2-enhanced green fluorescent protein (EGFP)
mice to determine the location and phenotype of Camkk2-
expressing cells within the BM microenvironment. The
analysis of reporter bone sections by immunofluorescence
revealed activity in individual single cells throughout the BM
(Figure 1A). A subset of EGFP-positive cells was located
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adjacent to the vascular endothelial marker VE-cadherin
(Figures 1Ac–d, high-magnification inset). We found that
approximately 20% of lineage (Lin)+ cells were EGFP
positive by flow cytometry. The reporter was active in
25–40% of Lin-cKit- (CD117) stem cell antigen-1- (Sca-) cells
and 5–10% of the Lin-cKit-Sca+ cells. Conversely, the EGFP
reporter was detectable in 95–100% of Lin-cKit+ cells
(Figures 1B and C). A detailed analysis of the HSPC
compartment revealed robust reporter activation in Lin-cK-
it+Sca- (KL) and Lin-cKit+Sca+ (KSL) cells (Figures 1B and C,
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Figure 1 Camkk2 expression is enriched in primitive HSPCs in vivo. (A) Femurs were harvested from control and Camkk2-EGFP reporter mice and sectioned for
immunofluorescent staining with VE-cadherin and anti-GFP antibodies (Aa, Ab; low magnification, Ac and insets high magnification) (n= 3 per genotype). (B) BM cells from
control and Camkk2-EGFP reporter mice were isolated, stained to identify HSPC subsets and analyzed by flow cytometry (top and bottom panels). (C) The reporter expression is
shown relative to lymphocyte EGFP intensity, which is considered CaMKK2 negative. The relative EGFP expression is quantitated in the right panels (n= 6 mice/genotype). Bars
graph reports mean±S.E.M. *, *** and **** refer to P-valueso 0.05, 0.005 and 0.001, respectively
CaMKK2 regulates hematopoietic regeneration
Luigi Racioppi et al
2
Cell Death and Disease
top panels). Additional KSL subset analyses using the
signaling lymphocyte activation molecules (SLAM) markers
CD150 and CD48 showed EGFP expression in the LT-HSC
population defined as KSL CD150+CD48- and multipotent
progenitors (MPP, KSL CD150-CD48-; Figures 1B and C,
bottom panels). The reporter was highly active in committed
hematopoietic progenitor populations 1 and 2 (HPC-1 and
HPC-2) defined as KSL CD150-CD48+ and CD150+CD48+ 21
(Figures 1B and C, bottom panels). Cumulatively, these data
suggest the capacity to initiate Ca2+-dependent signaling via
CaMKK2 is enriched in the most primitive hematopoietic
stem cells.
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Figure 2 Camkk2 regulates transcriptional program of hematopoietic stem cells. (a) Volcano plot comparison of DEGs in KSL cells isolated from BM of Camkk2 null and
control mice (WTand KO, respectively). Genes downregulated or upregulated in KO compared with WTare indicated as KO DN and KO UP, respectively. Color dots indicate genes
involved in the regulation of differentiation or reprogramming of mature hematopoietic cells to HSC. (b) GSEA of microarray data shows that gene signatures for genes enriched in
hematopoietic stem cells are significantly downregulated in KO KSL (upper). In contrast, genes enriched in late progenitors are significantly upregulated in KO KSL (lower).
(c) Loss of Camkk2 downregulates the quiescent gene signature in stem cells. Heatmap represents DEGs in quiescent stem cell signature. Q-Sign DN and UP indicate genes
downregulated and upregulated in quiescent stem cells. The color key of heatmaps indicates row-wise scaled RPKM values (z-score)
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Camkk2 regulates the HSPC transcriptional program. To
identify gene sets controlled by Camkk2 in HSPC, we
performed microarray analyses on KSL cells isolated from
WT and Camkk2 null mice and found 1289 genes were
significantly downregulated and 533 genes were upregulated
in Camkk2 null KSL compared with WT (Figure 2a). The lists
of the top differentially expressed genes (DEGs) are reported
in Supplementary Table S1 and S2. The gene set enrichment
analysis (GSEA)22 showed genes downregulated in Camkk2
null KSL were enriched in HSC,23,24 early progenitors,24 and
lymphoid-myeloid-affiliated genes (s-myly) primed in HSC24
(Figure 2b, upper panel; Supplementary Figure S1A). The
HSC-affiliated downregulated genes in Camkk2 KSL
included Hlf, Meis1, Pbx-1 and Prdm5. These genes
represent four of the eight genes capable of reprogramming
committed murine blood cells into HSC (Figure 2a).25
Conversely, genes affiliated with the late progenitor
signature23 (Figure 2b, lower panel), erythroid genes primed
in HSC,24 and granulocyte macrophage progenitor (GMP)-
specific genes (d-my)24 were significantly upregulated in
Camkk2 null KSL (Supplementary Figures S1B and C).
The pathways over represented by Camkk2 null KSL DEGs
included cell adhesion molecules (CAMs, P= 8.218e-8) and
chemokine signal pathway (P=0.0275; Supplementary Table
S2). We analyzed the gene expression affiliated with the
quiescent signature in various stem cells including hemato-
poietic, muscle and hair follicle stem cells.26We found 25% (18
of 71) of genes affiliated with a quiescent stem cell signature
(Q-Sign) were differentially expressed in Camkk2 null KSL.
Interestingly, 14 of 49 genes upregulated in Q-Sign (Q-Sign
UP) were downregulated in Camkk2 KO KSL (Figure 2c).
Moreover, none of the Q-Sign UP genes were upregulated in
Camkk2 null KSL (Figure 2c; P=0.0144). None of the 22
genes downregulated in quiescent stem cells (Q-Sign DN)
were downregulated in Camkk2 null KSL. In contrast, four
Q-Sign DN genes (Ccna2, Rrm2, Anln and Idh3) were
upregulated in Camkk2 null compared with WT KSL
(Figure 2c; P-value= 0.0075). This finding was corroborated
using gene signatures specifically affiliated with HSC quies-
cence and proliferative status (HQ-sign and HP-sign, respec-
tively).27 We found 15% of HQ-sign genes (40 of 264) were
significantly downregulated in Camkk2 null KSL. However,
only 3 of 264 genes were significantly upregulated in Camkk2
null KSL (Supplementary Figures S2A–C; P=0.0001). The
data indicate 12 of 313 genes in theHP-Signwere upregulated
in Camkk2 null KSL compared with WT and 3 of 264 were
downregulated in Camkk2 null KSL (Supplementary Figure
S2A and B; P=0.0632). Collectively, these findings indicate
the deletion of Camkk2 downregulates genes controlling
HSPC quiescence and concurrently upregulates genes
affiliated with the late progenitor signature.
Camkk2 null HSPC have increased proliferation
in vitro. We cultured KSL cells sorted from control and
Camkk2 null mice with thrombopoietin, SCF and Flt-3-ligand
cytokines (TSF) to analyze the effect of Camkk2 ablation on
HSPC proliferation in response to cytokines. In addition, we
mimicked the vascular niche microenvironment using non-
contact cultures with primary BM-derived endothelial cells
(BMECs). After 7 days, the numbers of total KL and KSL cells
were assessed. The cells recovered from cultures were then
functionally analyzed in methylcellulose cultures to examine
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Figure 3 Camkk2 null hematopoietic stem cells have increased proliferation in vitro. KSL cells were sorted from WTand Camkk2 null mice and cultured with TPO, SCF and
Flt-3L in the presence or absence of BM endothelial cells (TSF and ECs, respectively). Cell were harvested and analyzed on day 7. (a) Total cells number. (b and c) Absolute
numbers of KL and KSL cells. (d) Cells recovered at day 7 were plated in methylcellulose media for colony formation and colonies (CFUs). Graphs report total CFUs normalized
by total cell expansion. The experiment was replicated twice. Bars graph reports mean± S.E.M. *Po0.05, **Po0.01, ***Po0.005. **** Po0.001
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colony-forming unit (CFU) capacity. Regardless of the
genotype, significantly more total cells were recovered from
co-culture with BMEC compared with TSF alone (Figure 3a).
There was a slight increase in the numbers of total and KL
cells found in TSF cultures of Camkk2 null KSL compared
with WT cells (Figures 3b and c). Interestingly, the presence
of BMEC resulted in a more robust increase in both KL and
KSL recovered from Camkk2 null KSL compared with WT
cultures (Figures 3b and c). The progeny derived from
Camkk2 null KSL cultured in the presence of TSF had a
modest increase in functional colony formation compared
with WT cells (Figure 3d). In contrast, progeny derived from
Camkk2 null KSL cultured in the presence of BMEC
generated a significantly higher number of CFUs compared
with WT (Figure 3d). Cumulatively, these results show
Camkk2 null KSL cells have significantly higher proliferative
ability than WT cells in culture conditions mimicking the
hematopoietic niche.
Camkk2 null mice have improved survival and acceler-
ated hematopoietic recovery following total body irradia-
tion (TBI). We previously reported that under homeostatic
conditions, Camkk2 ablation does not affect survival and
proliferation of the KSL population in vivo.19 However, we
observed Camkk2 null HSPC have an increased ability to
proliferate in vitro (Figure 3). Therefore, we hypothesized
CaMKK2 restrains the proliferation of HSPC. Thus, Camkk2
ablation would accelerate the hematological recovery follow-
ing BM damage. To test this hypothesis, we injured the
hematopoietic compartment in vivo using total body γ-
irradiation (TBI; 700-900cGy) and then monitored mice for
survival, blood counts, and BM recovery (Figure 4a).
Using a single dose of 800cGy TBI, which is sufficient to kill
approximately 80% of control animals in 30 days (LD80/30), we
found 100% of Camkk2 null animals and 20% of control
animals survived for 430 days (Figure 4b, Po0.0001).
Although a higher radiation dose (900cGy, LD100/15;
Supplementary Figure S3A) killed all control animals, approxi-
mately 40% of Camkk2 null animals survived for 430 days
(Figure 3a, Po0.01).
We then monitored the peripheral blood cell count (CBC)
recovery of irradiated mice using a single sublethal radiation
dose (700cGy). Non-irradiated Camkk2 null mice have
significantly more monocytes and less white blood cells
(WBCs), neutrophils, and lymphocytes in blood compared
with WT mice. The number of red blood cells (RBCs) and
platelets were comparable in WT and Camkk2 null mice
(Supplementary Figure S3). The irradiated Camkk2 null mice
have a better ability to regenerate neutrophils, leukocytes and
RBC compared with WT mice (Supplementary Figures S3B
and S4C). In addition, the number of monocytes was also
significantly higher in TBI Camkk2 null mice compared with
WT mice (Supplementary Figure S3B). However, when
normalized for the basal level, we found WTand Camkk2 null
mice showed a comparable ability to regenerate monocytes
and platelets following TBI (Figure 4c and Supplementary
Figure S3B).
To examine the BM content during regeneration, we killed
700cGy TBI control and Camkk2 null animals on day 14 and
isolated BM for histology and flow cytometry analyses. The
histological analysis indicated Camkk2 null animals had
qualitatively higher BM cellularity than control mice
(Supplementary Figure S4A, left) and there were significantly
more cells in the marrow of irradiated Camkk2 null animals
compared with WT mice (Supplementary Figure S4B;
Po0.05). There were comparable numbers of WBMC in
non-irradiated WT and Camkk2 null mice (Supplementary
Figure 4B).
We assessed whether the accelerated hematopoietic
recovery was mediated by enhanced HSPC regeneration by
analyzing the KL and KSL cell content in BM on day 14
following 700cGy TBI. Although we found a trend of reduced
absolute KL and KSL number in non-irradiated marrow, there
were significantly more KL and KSL cells during hematopoietic
regeneration (Figure 4d). The SLAM KSL subsets were
analyzed in TBI and non-irradiated mice based on the
expression of CD48 and CD150 (Supplementary
Figure S4C). The data show an increase in the percentage
of LT-HSC in Camkk2 null mice under both homeostatic
conditions and following TBI (Supplementary Figure S4D,
left). In addition, the percentage of HPC-2 subsets was higher
only in TBI Camkk2 null mice compared with control mice
(Supplementary Figure S4D, right). Cumulatively, these data
indicate Camkk2 null mice have accelerated HSPC recovery
following radiation injury and this accounted for the faster
hematopoietic recovery.
Total body irradiated Camkk2 null mice have more
proliferating HSPC in BM. We examined the in vivo
sensitivity of HSPC to radiation-induced apoptosis to
determine the cellular basis of the accelerated hematopoietic
recovery in Camkk2 null mice. As previously reported,19
Camkk2 deficiency does not impair the survival of HSPC in
non-irradiated mice (Supplementary Figures S5A and S5B).
Our data show a slight increase in live (10–15%) Camkk2 null
KSL cells compared with WT KSL cells, but no differences in
KL cells were observed 24 h after 450cGy TBI
(Supplementary Figures S5C and S5D).
We examined the proliferative response of the KL and KSL
cells in the BM of regenerating control and Camkk2 null mice
on day 14 after 700cGy TBI. We found significantly more 5-
bromo-2'-deoxyuridine (BrdU) incorporation in Camkk2 null
KL and KSL cells during this period (Figure 4e). The results
indicate approximately 20% of control KSL cells are BrdU+,
but450% of Camkk2 null KSL cells are in cycle at day 14. To
test whether the functional capacity of regenerated stem cells
was decreased by the enhanced proliferation, we performed
competitive transplantation assays using control and Camkk2
null KSL CD34- cells harvested from the BM of 200cGy TBI
mice. We found radiation did not induce differential HSC
exhaustion or cause significant lineage skewing in the
peripheral blood of recipient mice (Supplementary
Figure S6). Cumulatively, these data demonstrate the loss of
Camkk2 enhanced the proliferation of regenerating HSPC,
which accelerates hematopoietic recovery.
Camkk2 null HSPC have a cell-intrinsic enhanced
regenerative capability in vivo. To establish the cell-
autonomous function of CaMMK2 on the regenerative
capability of HSPC in vivo, we isolated KSL CD34- cells from
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WT and Camkk2 null mice (CD45.2+) and transplanted the
cells into lethally irradiated B6.SJL recipient mice (CD45.1+)
with host competitor BM cells (Figure 5a). The recipient mice
were then monitored by CBC and CD45.2 chimerism was
assessed. After 4 months, the transplanted mice showing
comparable levels of CD45.2 chimerism were selected,
irradiated with 450cGy TBI, and then monitored for CD45.2
chimerism (Figures 5a and b). During the regenerative phase,
the CD45.2 chimerism in mice transplanted with WT KSL
remained at levels comparable to pre-TBI. In contrast, we
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found a significant increase in CD45.2 chimerism in mice
transplanted with Camkk2 null HSC (Figure 5c and
Supplementary Figure S7). These findings provide direct
evidence for a cell-intrinsic function of Camkk2 in regenerat-
ing HSPC because Camkk2 was ablated only in the
transplanted KSL CD34- cells.
CaMKK2 couples radiation signaling with AMPK anti-
proliferative pathways. To investigate CaMKK2 function in
radiation-induced signaling, we sorted lin- cKit+ cells (HSPC)
from the BM of control and Camkk2 null mice and irradiated
the cells in vitro. The HSPC were then incubated for 60 min in
culture medium and CaMKK2 and its known targets were
evaluated in total cell lysates by immunoblotting. As expected,
null mice lacked any detectable CaMKK2 protein in sorted
HSPC (Figure 6a). We found CaMKK2 loss did not impair the
level of phospho-CaMKI in non-irradiated or irradiated HSPC
(Figure 6a). There was no CaMKIV or phospho-CaMKIV
detected in homeostatic or irradiated cells (data not shown).
Interestingly, Camkk2 null non-irradiated HSPC had signifi-
cantly less phospho-AMPK and failed to induce phospho-
AMPK after radiation (Figure 6b). These results identify AMPK
as the primary canonical target of CaMKK2 in HSPC and
demonstrate CaMKK2 is required for coupling early radiation-
induced signaling with AMPK activation.
AMPK is an evolutionarily conserved energy sensor that
has an important role in cell proliferation, growth and
survival.28 AMPK is also an important negative regulator of
the Raptor-TSC-mTOR-S6K1 signaling pathway that controls
S6 ribosomal protein (S6rp) to positively regulate cell
proliferation. We measured the level of phospho-S6rp in
non-irradiated and irradiated HSPC and found comparable
levels of phospho-S6rp in non-irradiated WTand Camkk2 null
HSPC. In contrast, we detected more phospho-S6rp in
Figure 4 Camkk2 null mice have improved survival and accelerated hematopoietic recovery following TBI. (a) Scheme of TBI. Mice were TBI and monitored for survival,
blood cell count (CBC) and BM recovery. (b) Survival of WTand Camkk2 null mice (WTand KO, respectively) irradiated with 800cGy (n= 14 mice per genotype). The blue lines
indicate control and the red lines indicate Camkk2 null mice. (c) Hematopoietic recovery in WTand KO mice sublethally irradiated with 700cGy TBI and bled for CBC analysis of
total WBCs, platelets (PLT), RBCs, neutrophils (NE), monocytes (Mo) and lymphocytes (Ly) (n= 6 and 9 mice for WTand Camkk2 null mice, respectively). (d) WTand KO mice
(n= 10 per group) were irradiated with 700cGy TBI and euthanized 14 days after irradiation. WTand KO non-irradiated mice were used as controls (n= 6 mice per group). Upper
and lower bar graphs report mean ±S.E.M. of KL and KSL, respectively. (e) BrdU incorporation in KL and KSL cells in vivo during regeneration. WTand KO mice were irradiated
with 700cGy TBI, and after 14 days were pulsed with BrdU in vivo for 2 h before killing. Dot plots of KL and KSL cells and BrdU incorporation on day 14 after radiation (top panels).
BrdU staining FACS profiles in KL and KSL subsets (upper panels). Bars graph reports mean± S.E.M. The percentage of BrdU+ cells is shown in lower graphs (bottom panels;
n= 6 per genotype). *Po0.05, **Po0.01, ***Po0.005, ****Po0.001
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Figure 5 Camkk2 null HSC have a cell-intrinsic enhanced regenerative capability in vivo. KSL CD34- cells were isolated from WT and Camkk2 null mice (WT and KO,
respectively) and transplanted in lethally irradiated recipient mice with CD45.1 competitor BM. The recipient mice receiving WT or KO KSL CD34- cells were monitored for
4 months. Subsequently, mice showing comparable percentages of WTor KO donor CD45.2 cells were irradiated with 450cGy TBI and bled weekly after irradiation (n= 6 per
group). (a) Scheme of the experiment. (b) CD45.2 chimerism in mice reconstituted with WT or KO KSL CD34- before receiving 4.5Gy TBI. (c) Donor CD45.2 chimerism was
monitored by flow cytometry and the results are expressed as fold change over the basal level (pre-TBI). Bars graph reports mean± S.E.M. *Po0.05, **Po0.01
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irradiated Camkk2 null HSPC compared with WT HSPC (1.3-
versus 2.3-fold change, respectively; Figure 6b).
The p53 protein is an important effector of radiation
signaling and its role in the control of apoptosis, quiescence
and proliferation of HSPC is well documented.29,30 Moreover,
AMPK is a relevant upstream activator of the p53 pathway.31,32
Therefore, we hypothesized the CaMKK2-AMPK axis is
involved in radiation signaling and regulates p53 stabilization.
We measured p53 in WT and Camkk2 null HSPC irradiated
in vitro with 300cGy or left non-irradiated. The non-irradiated
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Figure 6 CaMKK2 couples radiation signaling with the AMPK anti-proliferative pathway. HSPC (KL+KSL) were isolated from WTand Camkk2 null (KO) mice and irradiated
in vitro with 400cGy or left non-irradiated. Cells were then cultured for 1-h in regular medium. Protein expression was normalized by actin and expressed as fold change over basal
(non-irradiated WT HSPC), and is reported on the top of each lane. (a) Immunoblots of CaMKK2, phospho-CaMK1 (pCaMK1) and actin. (b) Immunoblots of Tp53, phosphorylated
AMPK and S6rp (pAMPK and pS6rp, respectively). (c-e) M1 myeloid progenitor cells were transduced with lentiviral vectors expressing a short hairpin sequence for silencing
Camkk2 or a control sequence (ShCamkk2 and Ctrl, respectively). Ctrl and ShCamkk2 M1 cells were then irradiated or left non-irradiated. One-hour after irradiation, M1 cell
protein expression was assessed by immunoblotting. (c) Expression of CaMKK2 and actin. (d) Immunoblots of pAMPK, pS6rp, actin and Tp53 of M1 cells irradiated with
increasing doses of radiation or left non-irradiated. (e) M1 cells transduced with Ctrl and ShCamkk2 lentiviral vectors were 300cGy irradiated and cultured for 24 h in regular
medium in the presence or absence of AICAR (100 μM), a cell permeable AMPK agonist (Top and lower, respectively). Cell number was determined using a colorimetric assay,
and the results are expressed as fold change of non-irradiated cells cultured in the absence of AICAR. Bars graph reports mean± S.E.M. The experiments included in this figures
were replicated at least three times. (f) Modeling the radiation-induced CaMKK2-dependent signal pathway. **Po0.01,***Po0.005, ****Po0.001
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HSC from WT and Camkk2 null mice expressed comparable
low levels of p53 (Figure 6b). However, WT HSPC accumu-
latedmore p53 comparedwith Camkk2 null HSPC in response
to radiation (Figure 6b).
To further validate CaMKK2 function in radiation-induced
signaling, we used lentiviral vectors to silence the expression
of Camkk2 (ShCamkk2) in the M1 myeloid progenitor cell line
(Figure 6c). Camkk2 deficiency induced similar changes in the
gene expression profile of KSL and M1 cells (Supplementary
Figures S8A and S8B). We measured the levels of phospho-
AMPK, phospho-S6rp and p53 in control and ShCamkk2
M1 cells exposed to increasing radiation doses (300-500cGy)
or left non-irradiated (Figure 6d). The radiation injury
increased the phospho-AMPK and p53 levels in M1 control
cells. In contrast, a minor increase in the phospho-AMPK and
p53 levels was detected in ShCamkk2 M1 cells (Figure 6d).
Radiation increased phospho-S6rp levels in both control and
ShCamkk2 M1 irradiated cells, which suggests M1 cells may
have additional CaMKK2-independent signals that control
phosphorylation of S6rp after radiation.
To determine the functional effects of Camkk2 deficiency in
M1 cells, we exposed control and ShCamkk2 M1 cells to
300cGy with or without a cell permeable AMPK agonist and
then determined the number of live M1 cell 24 h after
irradiation. We found ionizing radiation decreased the pro-
liferation of M1 control cells but did not affect ShCamkk2
M1 cells (Figure 6e, top). The addition of the AMPK
agonist 5-aminoimidazole-4-carboxamide 1-β-D-ribofurano-
side, (AICAR), to the culture media reverted the refractory
phenotype of ShCamkk2 M1 cells (Figure 6e, bottom). There
was no increase in cell death observed following radiation or
AICAR treatment (data not shown). Collectively, these findings
corroborate our hypothesis and demonstrate CaMKK2 is part
of the signal pathway that activates AMPK/p53 signaling and
mediates the anti-proliferative effect of radiation damage.
Pharmacologic inhibition of CaMKK2 enhances hemato-
poietic regeneration in vivo. We hypothesized that phar-
macologic inhibition of CaMKK2 increases survival and
HSPC recovery following TBI. To test this relevant transla-
tional implication of our findings, we delivered a lethal
radiation dose of 900cGy TBI (LD100/15) and then treated
the animals with either vehicle or the selective CaMKK2
inhibitor STO-609. The administration of STO-609 at a dose
of 10 μM/kg on days 1, 2 and 3 post-TBI significantly
prolonged survival in the LD100/15 model (Figures 7a and b).
This dose of STO-609 was selected based on previous in vivo
studies of the compound.17,33 We next evaluated the effects
of STO-609 treatment on HSPC of mice receiving 500cGy
TBI and found more total BM cells and HSPC in the BM of
mice 9 days after TBI (Figures 7c and d). Collectively, our
findings indicate the transient administration of STO-609 after
BM injury improves survival and expands HSPC.
Discussion
Our results uncover an important role for CaMKK2 in the
mechanism controlling HSPC regeneration. CaMKK2 controls
transcriptomic programs associated with stem cell quiescence
and its loss stimulates HSPC regeneration in vivo.
Interestingly, we demonstrate that pharmacological inhibition
of Camkk2 improves survival and accelerates HSPC recovery
following hematopoietic radiation injury.
The interrelated processes of quiescence, proliferation and
differentiation are tightly regulated in stem cells and this
balance controls tissue regeneration after severe injuries.26
Extrinsic and HSC autonomous factors are involved in the fine
tuning of these processes and defects in these molecular
machineries are associated with high proliferative phenotype,
significant decreases of HSC and progressive exhaustion of
the hematopoietic compartment that culminates in premature
death.34–36 We show Camkk2 deletion in HSPC significantly
downregulates genes affiliated with the quiescent stem cell
signature.26,27 However, under homeostatic conditions
Camkk2 null mice have only a slight decrease in HSPC
number19 associated with mild alterations in blood cell counts.
Camkk2 null mice do not develop a progressive exhaustion of
the hematopoietic compartment or blood cancer with age (LR
personal communication). These findings indicate Camkk2
loss does not affect HSPC under homeostatic conditions. On
the contrary, Camkk2 null HSPC have a hyper-proliferative
phenotype in vitro and an enhanced regenerative capability
following BM damage. Interestingly, in conditions that mimic
the functional cross talk in the niche, Camkk2 null KSL show
higher functionality than WT cells. Collectively, these findings
suggest CaMKK2 has a novel function in the signaling network
involved in quiescence and the regenerative response of HSC
in the niche.
We demonstrated CaMKK2 links proximal radiation signaling
to activation of the anti-proliferative AMPK/p53 signaling path-
ways (Figure 6f). Under homeostatic conditions, CaMKK2 loss
decreases phospho-T172 AMPK levels. This result suggests
other upstream kinases such as Lkb1 contribute to AMPK
regulation in quiescent HSC.36–38 The CaMKK2-AMPK axis is
dispensable for maintaining homeostatic HSC, which is sup-
ported by the findings that germ-line deletion of Camkk219 or
deletion of Ampk in the hematopoietic compartment38 does not
impair hematopoiesis. Conversely, Lkb1 deletion is associated
with a transient hyper-proliferative HSC response that is followed
by an AMPK/mTOR independent catastrophic HSC depletion,
pancytopenia and animal death.36–38 Ionizing radiation regulates
AMPK activation in endothelial cells,39 mouse embryonic
fibroblasts (MEFs)40 and cancer cells.41,42 However, the effect
of radiation on AMPK in HSPC is poorly understood and the
predominant upstream kinase responsible for radiation-induced
AMPK activation is unknown. Our results showCamKK2may be
the critical upstream kinase and we demonstrate radiation
activates AMPK in HSPC via CaMKK2. Camkk2 deletion
prevents the inhibitory effects exerted by acute activation of
AMPK on downstream effectors of mTOR signaling43 and
p53,31,32 which control HSC proliferation under
stress.19,36–38,43–45 The protein p53 is an important effector of
the anti-proliferative effects of radiation and studies have shown
short-term p53 inhibition following radiation damage facilitates
hematopoietic recovery and prevents development of radiation-
induced lymphomas.46–48 Importantly, p53 is a target of AMPK
kinase. Here, we demonstrate for the first time that CaMKK2 is
required for p53 accumulation following radiation injury.
Our findings have significant translational impact and
suggest pharmacological CaMKK2 inhibition accelerates
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hematopoietic recovery following TBI injury. Furthermore,
CaMKK2 inhibitionmay prevent blood cancers associated with
the radiation treatment. Pharmacological p53 inhibition has
been proposed to attenuate acute toxicity and decrease the
risk of radiation-related blood cancer development.46 How-
ever, p53 is ubiquitously expressed which may limit therapeu-
tic approaches. Conversely, CaMKK2 is restricted to a limited
number of cell types including HSPC and myeloid cells. The
restricted cellular expression of CAMKK2 makes it an
attractive target to selectively prevent radiation-induced
upregulation of p53 in HSPC and could limit the effects of
p53 activation while simultaneously reducing the potential side
effects associated with systemic p53 inhibition.
Materials and Methods
Mice. CaMKK2-EGFP transgenic reporter mice have been described previously.49
Radiation was delivered by a Shepherd Cs137γ-irradiator at a dose rate of approximately
600cGy per min. All animal experiments were performed according to protocols
approved by the Duke University Institutional Animal Care and Use Committee.
Antibodies. Anti-CaMKK (pan-KK) was from BD Biosciences (San Jose, CA,
USA), anti-phospho-S6rpS240/244, anti-phospho-AMPKαT172 and anti-AMPKα were
from Cell Signaling Technology (Danvers, MA, USA). Anti-phospho-CaMKIT177 was
from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-β-actin was from Sigma.
M1 cells and proliferation assay. M1 cells (ATCC TIB-192) were obtained
from Duke Cell Culture Facility (Durham, NC, USA). In proliferation experiments,
M1 cells were seeded at 2 × 104/ml per well into a 24-well plate. MTS Cell
Proliferation Assay Kit was from Abcam (Cambridge, MA, USA).
Isolation and FACS of HSPC. HSPC were sorted from mouse BM based on
surface expression of c-Kit, Sca-1, and low to negative expression of lineage
markers (lin-). KSL CD34- were used in reconstitution experiment as described.50 All
antibodies were purchased from BD Biosciences, BioLegend (San Diego, CA, USA)
or eBioscience (Waltham, MA, USA). Annexin-V/7AAD apoptosis kit was from BD
Biosciences. The cell sorting and analyses were performed on a FACSVantage cell
sorter or CANTO analyzer (Becton Dickinson, Franklin Lakes, NJ, USA).
Microarray analysis. KLS cells were sorted from BM directly into Buffer RLT
(Qiagen, Frederick, MD, USA). Microarray analysis was performed at Sequencing
and Genome Technologies Shared Resource (Duke University). Microarray data are
available at GEO (accession number: GSE95733).
Gene set enrichment analysis. GSEA22 was applied to our microarray
data. All genes were ranked by the fold change between the Camkk2 null and WT
control samples. Normalized enrichment score (NES) and adjusted q-values were
computed utilizing the GSEA method, based on 1000 random permutations of the
ranked genes. Gene set collections (MSigDB, http://www.broadinstitute.org/gsea/
msigdb/) was used to determine enriched pathways.
In vivo transplantation experiments. For competitive engraftment
assays, the total BM cells were isolated from femurs and tibiae of WT and Camkk2
null (CD45.2 background). c-Kit-positive cells were enriched using anti-CD117/c-Kit
microbeads (Miltenyi Biotec, Auburn, CA, USA). The KSL CD34- stem cells
(CD45.2) were then sorted and 1000 cells were injected with 5x105 competitor
whole BM (CD45.1) into lethally irradiated (split dose totaling 10Gy) recipient B6-
CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) mice via the retro-orbital sinus. In the same
experiments, KSL CD34- cells were sorted from BM of Camkk2 null or control mice
treated with 200cGy 90 days before transplant. For lineage analysis, peripheral
blood cells were collected and prepared as described.51 In some experiments,
transplanted mice were monitored for up to 4 months, and then mice received
450cGy TBI. Mice were finally monitored for chimerism.
In vitro proliferation with endothelial cells and methylcellulose
assays. Primary BMECs were generated as described.8 For liquid culture
experiments, freshly sorted KSL cells from control or Camkk2 null mice were plated
in 2% FCS-medium (X-Vivo15, Lonza, Portsmouth, NH, USA) supplemented with
50 μM 2-mercaptoethanol, SCF (50 ng/ml) and Flt-3 (30 ng/ml). After culturing for the
indicated time, live cells were counted using Trypan blue exclusion. For methylcellulose
assays, the recovered cells were plated in complete methylcellulose medium (StemCell
Technologies, Vancouver, BC, Canada, catalog number M3434). The colony numbers
were counted 8–10 days after plating.
Immunofluorescence staining of bone sections. Femurs were
decalcified, embedded in OCT media (Sakura Finetek, Torrance, CA, USA) and
10 μm sections were cut using the CryoJane tape system (Instrumedics Inc.,
Hackensack, NJ, USA) as described.52 To assess BM cellularity, sections were
stained with hematoxylin/eosin. Vasculature and EGFP+ cells were identified with
anti-mouse VE-Cadherin (Abcam) and anti-GFP antibodies (Abcam). The nuclear
dye DAPI (Invitrogen, Waltham, MA, USA) was included in all stains. Images were
obtained using an Axiovert 200 microscope (Carl Zeiss, Thornwood, NY, USA).
Immunoblotting. Immunoblots were performed according with the protocol
described previously,49 and visualized on an Odyssay CLx imager (LI-COR
Biosciences, Lincoln, NE, USA). Image Studio software (Lincoln, NE, USA) was
used for quantitation.
ShRNA lentivirus. shRNA3145 (TRCN0000028776) against Camkk2 and the
negative control pLKO (TRCN0000241923) were obtained from Open Biosystems
(Huntsville, USA). M1 cells were infected with shRNA3145 or pLKO virus containing
sham shRNA pLKO vector, or Camkk2 (3142, 3143 or 3145 clones) shRNA vector
using polybrene as per the manufacturer’s instruction. Cells were then selected and
maintained in media with puromycin.
Statistical analysis. In mice studies, a power calculation of sample size was
performed with the help of the Duke University Biostatistic core service. A two-tailed
Student’s t-tests and one-way ANOVA were used to determine statistical
significance. A P-value o0.05 was considered significant. The variance was
comparable between each group of data that was statistically compared. The
statistical significance was determined using GraphPad Prism 7 software
(GraphPad Software, Inc., La Jolla, CA, USA).
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